FDAnews Drug Daily Bulletin
Pharmaceuticals / Submissions and Approvals

FDA Approves Monthly Buprenorphine MAT for Opioid Use Disorder

Dec. 12, 2017

The FDA approved Invidior’s Sublocade, the first once-monthly buprenorphine injectable as a medication-assisted treatment for opioid use disorder.

Buprenorphine, a partial opioid agonist, is one of three drugs approved as an opioid MAT. First approved in 1981, it is currently available as a generic tablet, dissolvable film or implant.

Patients seeking treatment should be offered all three options, including naltrexone and methadone, to allow patients to receive the best-suited therapy, said FDA Commissioner Scott Gottlieb, who described agency plans to encourage wider use of MATs, as well as a more efficient approval pathway.

The FDA said Sublocade should be used as part of a complete treatment program that includes counseling and psychosocial support. The treatment is indicated for adult patients that have started using a transmucosal version of the drug, and have been on a stable dose for at least one week.

View today's stories